Abstract
In the adult population with newly diagnosed chronic myeloid leukemia (CML), variant translocations are usually not considered to be impairing the prognosis, whereas some additional cytogenetic abnormalities (ACAs) are associated with a negative impact on survival. Because of the rarity of CML in the pediatric population, such abnormalities have not been investigated in a large group of children with CML. The prognostic relevance of variant t(9;22) and ACAs at diagnosis was assessed in 301 children with CML in the chronic phase who were enrolled in the International Registry for Chronic Myeloid Leukemia in Children and Adolescents. Overall, 19 children (6.3%) presented with additional cytogenetic findings at diagnosis: 5 children (1.7%) had a variant t(9;22) translocation, 13 children (4.3%) had ACAs, and 1 had both. At 3 years, for children with a classic translocation, children with ACAs, and children with a variant t(9;22) translocation who were treated with imatinib as frontline therapy, the probability of progression-free survival (PFS) was 95% (95% confidence interval [CI], 91%-97%), 100%, and 75% (95% CI, 13%-96%), respectively, and the probability of overall survival (OS) was 98% (95% CI, 95%-100%), 100% (95% CI, 43%-98...Continue Reading
References
Jul 15, 1976·International Journal of Cancer. Journal International Du Cancer·F MitelmanL Brandt
Jan 1, 1987·Cytogenetics and Cell Genetics·M De Braekeleer
Jun 1, 1973·Nature·J D Rowley
Jul 1, 1984·Cancer Genetics and Cytogenetics·R BernsteinB Mendelow
Jan 1, 1993·Leukemia & Lymphoma·F Mitelman
Feb 13, 2002·Leukemia·C SchochT Haferlach
Apr 30, 2002·Genes, Chromosomes & Cancer·Ivan F LoncarevicUwe Claussen
Apr 29, 2003·British Journal of Haematology·Alistair G ReidElisabeth P Nacheva
Apr 3, 2004·British Journal of Haematology·Maha M T El-ZimaityJorge E Cortes
Feb 8, 2006·Cancer·Jorge E CortesHagop M Kantarjian
Mar 9, 2006·Blood·Timothy HughesJohn M Goldman
Feb 27, 2007·Cancer Genetics and Cytogenetics·Madhavi GorusuMin Fang
Jan 12, 2010·Bone Marrow Transplantation·L ScruccaF Aversa
Mar 25, 2010·Acta Oncologica·Fabio StagnoFrancesco Di Raimondo
Mar 31, 2011·Blood·Giulia MarzocchiUNKNOWN Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Working Party on Chronic Myeloid Leukemia
Jun 28, 2011·Blood·François Guilhot
Nov 1, 2011·Blood·Alice FabariusUNKNOWN Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group
Jun 14, 2012·Blood·Simona LuattiUNKNOWN Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on CML
Jun 28, 2013·Blood·Michele BaccaraniRüdiger Hehlmann
Feb 4, 2016·Leukemia·Z ChenS Hu
Mar 24, 2016·Blood·Wei WangShimin Hu
Jun 4, 2016·Blood·François Guilhot
Citations
Oct 5, 2018·International Journal of Laboratory Hematology·Mingming XueBei Liu
Nov 16, 2018·Journal of Cellular Physiology·Ali Amin AsnafiTina Vosughi
Dec 5, 2018·Pediatric Blood & Cancer·Claudete Esteves KlumbRaquel Ciuvalschi Maia
Mar 29, 2019·Blood·Nobuko Hijiya, Meinolf Suttorp
Aug 1, 2020·British Journal of Haematology·Graeme SmithUNKNOWN British Society for Haematology
Oct 28, 2017·Expert Review of Clinical Pharmacology·Meinolf SuttorpEberhard Schleyer
Sep 3, 2020·World Journal of Clinical Oncology·Meinolf SuttorpFrédéric Millot
Nov 20, 2019·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Amro Mohamed Sedky El-GhammazMohamed Osman Azzazi
Oct 10, 2020·Pediatric Blood & Cancer·Adalet Meral GünesMeinolf Suttorp
Mar 7, 2021·Cancers·Meinolf SuttorpMarkus Metzler
May 15, 2019·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Frédéric MillotMeinolf Suttorp
Aug 24, 2021·Analytical Cellular Pathology (Amsterdam)·Muhammad AsifMahmood Rasool